Tafoxiparin
Priming of Labor in term-pregnant women with an unripe cervix planned for induction
Phase 2bActive
Key Facts
Indication
Priming of Labor in term-pregnant women with an unripe cervix planned for induction
Phase
Phase 2b
Status
Active
Company
About Dilafor
Dilafor is a clinical-stage biotech addressing a significant unmet need in obstetrics: the high complication rates from medically planned labor inductions, which affect 30-50% of term pregnancies. Its lead asset, tafoxiparin, has demonstrated promising efficacy and safety in a Phase IIb study, significantly improving cervical ripening and spontaneous labor onset rates. The company is now positioned to advance tafoxiparin into later-stage development, aiming to provide a novel, physiology-based therapeutic to improve outcomes for mothers and infants globally. Dilafor operates as a private entity, leveraging academic collaborations to build its pipeline.
View full company profile